1.12
-0.41 (-26.73%)
| Previous Close | 1.53 |
| Open | 1.21 |
| Volume | 6,566,256 |
| Avg. Volume (3M) | 2,448,110 |
| Market Cap | 6,793,679 |
| Price / Book | 1.26 |
| 52 Weeks Range |
| Operating Margin (TTM) | -148,318.41% |
| Diluted EPS (TTM) | 1.72 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 10.75% |
| Current Ratio (MRQ) | 3.02 |
| Operating Cash Flow (TTM) | -10.24 M |
| Levered Free Cash Flow (TTM) | -6.32 M |
| Return on Assets (TTM) | -116.11% |
| Return on Equity (TTM) | -208.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Azitra Inc | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | 0.0 |
| AI Insight | NA |
| Weighted Average | -0.40 |
Select this tab to load the latest available analysis.
|
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.95% |
| % Held by Institutions | 4.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dauntless Investment Group, Llc | 30 Jun 2026 | 1,129,219 |
| Stonepine Capital Management, Llc | 30 Jun 2026 | 528,548 |
| Nantahala Capital Management, Llc | 30 Jun 2026 | 221,361 |
| Tower Research Capital Llc (Trc) | 30 Jun 2026 | 1,950 |
| Corient Private Wealth Lp | 30 Jun 2026 | 1,445 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |